Lonza plugs EU cell and gene therapy manufacturing gap through PharmaCell buy – BioPharma-Reporter.com
BioPharma-Reporter.com |
Lonza plugs EU cell and gene therapy manufacturing gap through PharmaCell buy
BioPharma-Reporter.com The deal sees Switzerland-headquartered contract development and manufacturing organisation (CDMO) add the assets and staff of PharmaCell to strengthen its cell and gene therapy offerings. “We had a manufacturing gap in the European market, … |
